Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Professor Wisia Wedzicha
Professor Wisia Wedzicha, National Heart & Lung Institute, Imperial College London and member of the GOLD scientific committee, talks about why the GOLD recommendations for initial COPD therapy changed.
Use of GOLD content in this video © 2023 Global Strategy for the Diagnosis, Management and Prevention of COPD. All rights reserved. Use is by express license from the owner.
GOLD recommends classes of medicines, not specific products.
Anoro Ellipta is indicated for maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@GSK.com.
June 2024 | PM-GB-UCV-WCNT-240003 (V1.0)
